18%
of FDA-approved small molecule drugs since 2014 have collaborated with us
of FDA-approved small molecule drugs since 2014 have collaborated with us
active Drug Master Files (DMFs) to date
completed solid form projects across a range of structurally diverse and complex APIs
Discover new ways to advance your science with Veranova. Our capabilities span a wide range of development technologies and specialties—all backed by comprehensive industry knowledge and experience.
Extensive capabilities across both process and analytical development.
Tech capabilities that encompass solid form sciences including crystallization development and particle engineering.
Specialty capabilities include highly potent APIs and drug linkers in addition to complex small molecule chemistry.
Whether you need a partner in development or an experienced leader to navigate complex scale-up, Veranova can help. Our deep knowledge of API manufacturing and processes is supported by a collaborative, consultative approach to ensure your expectations and milestones are met.
With deep technical expertise and impressive flexibility, we help develop solutions and processes that support innovation.
To support clinical trials, we establish manufacturing processes and analytical methods that are scalable and collaborative.
We efficiently manage manufacturing APIs in commercial quantities with our agile network and supply chain.
We help you optimize your manufacturing processes and scale-up your services with confidence, speed and flexibility.
From reducing our environmental footprint and ensuring the highest standards of product safety to upholding ethical practices and promoting inclusion, our commitment to growth, environmental sustainability and responsible innovation is core to achieving our mission and creating long-term value.
Learn more about our corporate responsibility strategy
Nanomilling is a particle-size reduction technique that can enhance the dissolution rate of poorly soluble active pharmaceutical ingredients (APIs) and therefore their bioavailability. This technology can also open opportunities for novel formulations.
Read our latest eBook that explores the critical challenges shaping ADC development today, from analytical strategy and impurity control to linker technology innovations and evolving regulatory standards. It also examines the collaborative expertise needed to bring these transformative therapies to patients.
In this article, Kishore Vatsavai, Principal Scientist, outlines the key takeaways from the FDA’s draft guidance, offers real-world examples of how AI is being applied in drug development today, and shares strategies to help mitigate bias and model drift, along with practical resources for those interested in learning more.
Discover new ways to advance your science with Veranova.
Contact us